menu
    • menu
    [{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Semuloparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Hematology","graph2":"Phase II","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Veralox Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veralox Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Hematology","graph2":"Phase II","graph3":"Veralox Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Veralox Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Veralox Therapeutics \/ Hatteras Venture Partners"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Hematology","graph2":"Phase II","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veralox Therapeutics \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Veralox Therapeutics \/ Celerion"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Roledumab","moa":"Blood group Rh(D) polypeptide","graph1":"Hematology","graph2":"Phase II","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"Mario Negri Institute for Pharmacological Research","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Mario Negri Institute for Pharmacological Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mario Negri Institute for Pharmacological Research \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Mario Negri Institute for Pharmacological Research \/ Amgen Inc"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"aptamers||CCL2","graph1":"Hematology","graph2":"Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"aptamers||CCL2","graph1":"Hematology","graph2":"Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Hematology","graph2":"Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"NM8074","moa":"CFB","graph1":"Hematology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovelMed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"CFB","graph1":"Hematology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovelMed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Eptacog Alfa","moa":"Coagulation factor VII","graph1":"Hematology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Film, Orally Dissolving","sponsorNew":"TAHO Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Film, Orally Dissolving","sponsorNew":"TAHO Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Pediatric Heart Network | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Pediatric Heart Network | Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Pediatric Heart Network | Pfizer Inc"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EP-7041","moa":"Coagulation factor XI (F11)","graph1":"Hematology","graph2":"Phase II","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"eXIthera Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"eXIthera Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Hematology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Hematology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apellis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Essen","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Hematology","graph2":"Phase II","graph3":"University Hospital, Essen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Essen \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Essen \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Mario Negri Institute for Pharmacological Research","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ITALY","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"Cemdisiran","moa":"Complement C5 mRNA","graph1":"Hematology","graph2":"Phase II","graph3":"Mario Negri Institute for Pharmacological Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mario Negri Institute for Pharmacological Research \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Mario Negri Institute for Pharmacological Research \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"Cemdisiran","moa":"Complement C5 mRNA","graph1":"Hematology","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Hematology","graph2":"Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Peking Union Medical College Hospital \/ Celgene Corporation"},{"orgOrder":0,"company":"University Hospital, Limoges","sponsor":"Ministry of Health, France | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Hematology","graph2":"Phase II","graph3":"University Hospital, Limoges","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Limoges \/ Ministry of Health, France | Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Limoges \/ Ministry of Health, France | Celgene Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Hematology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Celgene Corporation"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Hematology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Hematology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Hematology","graph2":"Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Hematology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Western New England University","sponsor":"Quercis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Zafirlukast","moa":"Cysteinyl leukotriene receptor 1","graph1":"Hematology","graph2":"Phase II","graph3":"Western New England University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western New England University \/ Quercis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Western New England University \/ Quercis Pharma"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Posaconazole","moa":"Cytochrome P450 51","graph1":"Hematology","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Seoul National University Hospital \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Merck & Co"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Quintiles Inc"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Covis Pharma \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Norgine"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Covis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.28999999999999998,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Norgine"},{"orgOrder":0,"company":"Baptist Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Thiotepa","moa":"DNA","graph1":"Hematology","graph2":"Phase II","graph3":"Baptist Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baptist Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Baptist Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Knopp Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"DRD","graph1":"Hematology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Knopp Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Knopp Biosciences"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cobimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Genentech"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"SHP655","moa":"enzymes","graph1":"Hematology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"MAA868","moa":"Factor XI\/XIa","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"FBS0701","moa":"Ferroportin","graph1":"Hematology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"University of Sao Paulo","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase II","graph3":"University of Sao Paulo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sao Paulo \/ CSL Behring","highestDevelopmentStatusID":"8","companyTruncated":"University of Sao Paulo \/ CSL Behring"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Baxter Healthcare Corporation \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Fibrin Sealant (Human)","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Peking University Cancer Hospital & Institute | Second Affiliated Hospital, Zhejiang University | Jiangsu Cancer Institute & Hospital | The First Affiliated Hospital with Nanjing Medical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Peking University Cancer Hospital & Institute | Second Affiliated Hospital, Zhejiang University | Jiangsu Cancer Institute & Hospital | The First Affiliated Hospital with Nanjing Medical","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Jiuyuan Gene Engineering \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Peking University Cancer Hospital & Institute | Second Affiliated Hospital, Zhejiang University | Jiangsu Cancer Institute & Hospital | The First Affiliated Hospital with Nanjing Medical"},{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Jiuyuan Gene Engineering \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ National Institutes of Health"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Fudan University","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Fudan University"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Fudan University | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Nanfang Hospital, Southern Medical University | The Affiliated Hospital of Qingdao University | Tongji Hospital | The Affiliated Tumor Hospital of Nantong Universi","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Fudan University | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Nanfang Hospital, Southern Medical University | The Affiliated Hospital of Qingdao University | Tongji Hospital | The Affiliated Tumor Hospital of Nantong Universi","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Fudan University | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Nanfang Hospital, Southern Medical University | The Affiliated Hospital of Qingdao University | Tongji Hospital | The Affiliated Tumor Hospital of Nantong Universi"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Fudan University | Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Fudan University | Sun Yat-sen University","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Fudan University | Sun Yat-sen University"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Filgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"LJPC-401","moa":"Hepcidin (HAMP)","graph1":"Hematology","graph2":"Phase II","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"La Jolla Pharmaceutical \/ PRA Health Sciences","highestDevelopmentStatusID":"8","companyTruncated":"La Jolla Pharmaceutical \/ PRA Health Sciences"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BGE-117","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BGE-117","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BGE-117","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"Ainos","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"Interferon Alpha","moa":"IFNAR","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Undisclosed"},{"orgOrder":0,"company":"Ainos","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"Interferon Alpha","moa":"IFNAR","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Lind Partners"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ALXN1830","moa":"IgG receptor FcRn large subunit p51","graph1":"Hematology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ALXN1830","moa":"IgG receptor FcRn large subunit p51","graph1":"Hematology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"ALXN1830","moa":"IgG receptor FcRn large subunit p51","graph1":"Hematology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"M281","moa":"IgG receptor FcRn large subunit p51","graph1":"Hematology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"RVT-1401","moa":"IgG receptor FcRn large subunit p51","graph1":"Hematology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"UCB7665","moa":"IgG receptor FcRn large subunit p51","graph1":"Hematology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"UCB Pharma S.A \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Parexel"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BCD-131","moa":"IL-1 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Neumedicines","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Recombinant Human Interleukin-12","moa":"IL-12 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Neumedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumedicines \/ Department of Health and Human Services","highestDevelopmentStatusID":"8","companyTruncated":"Neumedicines \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Neumedicines","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Recombinant Human Interleukin-12","moa":"IL-12 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Neumedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumedicines \/ Department of Health and Human Services","highestDevelopmentStatusID":"8","companyTruncated":"Neumedicines \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Hematology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Hematology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Hematology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Hematology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Acceleron Pharma"},{"orgOrder":0,"company":"Medicure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban Hydrochloride Monohydrate","moa":"||Integrin alpha-IIb\/beta-3","graph1":"Hematology","graph2":"Phase II","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicure \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Hematology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MD Anderson Cancer Center \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"University of Leipzig","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Hematology","graph2":"Phase II","graph3":"University of Leipzig","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Leipzig \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Leipzig \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Haukeland University Hospital","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NORWAY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"Haukeland University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Haukeland University Hospital \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Haukeland University Hospital \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AustinPx","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"AustinPx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AustinPx \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"AustinPx \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Cancer Institute | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Kingston Health Sciences Centre | Sunnybrook Health Sciences Centre | Heart and Stroke Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Monoferric","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Health Network, Toronto \/ Kingston Health Sciences Centre | Sunnybrook Health Sciences Centre | Heart and Stroke Foundation","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Kingston Health Sciences Centre | Sunnybrook Health Sciences Centre | Heart and Stroke Foundation"},{"orgOrder":0,"company":"AbFero Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SP-420","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"AbFero Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbFero Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbFero Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbFero Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SP-420","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"AbFero Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbFero Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbFero Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"SPD602","moa":"Iron (Fe)","graph1":"Hematology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"SPD602","moa":"Iron (Fe)","graph1":"Hematology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"SPD602","moa":"Iron (Fe)","graph1":"Hematology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferrous Sulfate","moa":"Iron stores","graph1":"Hematology","graph2":"Phase II","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rockwell Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rockwell Medical \/ Undisclosed"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferrous Sulfate","moa":"Iron stores","graph1":"Hematology","graph2":"Phase II","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rockwell Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rockwell Medical \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Servier | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Hematology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Servier | Gateway for Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Servier | Gateway for Cancer Research"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb | Damon Runyon Cancer Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Hematology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb | Damon Runyon Cancer Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb | Damon Runyon Cancer Research Foundation"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Diacerein","moa":"JAK1\/TYK2","graph1":"Hematology","graph2":"Phase II","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TWi Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TWi Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"University of Arkansas","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Hematology","graph2":"Phase II","graph3":"University of Arkansas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Arkansas \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"University of Arkansas \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership | Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Hematology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership | Leukemia and Lymphoma Society","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership | Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Hematology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Hematology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Sanofi"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"Imago BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at San Antonio \/ Imago BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"University of Texas Health Science Center at San Antonio \/ Imago BioSciences"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":1.3500000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":1.3500000000000001,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Merck & Co"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":1.3500000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":1.3500000000000001,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Merck & Co"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"PTG-300","moa":"peptides","graph1":"Hematology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"peptides","graph1":"Hematology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protagonist Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keryx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"Phosphate","graph1":"Hematology","graph2":"Phase II","graph3":"Keryx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keryx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keryx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Carbohydrate","year":"2018","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Wayne State University","sponsor":"Children's Hospital of Michigan | American Regent","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Wayne State University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wayne State University \/ Children's Hospital of Michigan | American Regent","highestDevelopmentStatusID":"8","companyTruncated":"Wayne State University \/ Children's Hospital of Michigan | American Regent"},{"orgOrder":0,"company":"GALENA BIOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Anagrelide Hydrochloride","moa":"Phosphodiesterase 3","graph1":"Hematology","graph2":"Phase II","graph3":"GALENA BIOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GALENA BIOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GALENA BIOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3-kinase p110-delta subunit","graph1":"Hematology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3-kinase p110-delta subunit","graph1":"Hematology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3-kinase p110-delta subunit","graph1":"Hematology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Rocket Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"RP-L301","moa":"PKLR","graph1":"Hematology","graph2":"Phase II","graph3":"Rocket Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rocket Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Rocket Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"RP-L301","moa":"PKLR","graph1":"Hematology","graph2":"Phase II","graph3":"Rocket Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rocket Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tebapivat","moa":"PKLR","graph1":"Hematology","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Hematology","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Hematology","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Desogestrel","moa":"Progesterone receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Progesterone receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Haemostatix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Peprostat","moa":"Prostate-specific antigen","graph1":"Hematology","graph2":"Phase II","graph3":"Haemostatix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Haemostatix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haemostatix \/ Undisclosed"},{"orgOrder":0,"company":"Haemostatix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Peprostat","moa":"Prostate-specific antigen","graph1":"Hematology","graph2":"Phase II","graph3":"Haemostatix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Haemostatix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haemostatix \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BMS-986141","moa":"Proteinase activated receptor 4","graph1":"Hematology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BMS-986141","moa":"Proteinase activated receptor 4","graph1":"Hematology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome complex (IP)||PSMB9","graph1":"Hematology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Hematology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Hematology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"Duke University","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Hematology","graph2":"Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Duke University \/ Grifols International"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors||Serine protease","graph1":"Hematology","graph2":"Phase II","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AcelRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AcelRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Hematology","graph2":"Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado, Denver \/ Bayer AG"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"National Heart, Lung, and Blood Institute | National Cancer Institute | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Antithymocyte Globulin","moa":"T-cell surface glycoprotein CD1a (CD1A)","graph1":"Hematology","graph2":"Phase II","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical College of Wisconsin \/ National Heart, Lung, and Blood Institute | National Cancer Institute | Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Medical College of Wisconsin \/ National Heart, Lung, and Blood Institute | National Cancer Institute | Sanofi"},{"orgOrder":0,"company":"Geron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2010","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Hematology","graph2":"Phase II","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Geron \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"AMG531","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Novartis Pharmaceuticals Corporation | Qilu Hospital of Shandong University | The Second Affiliated Hospital of Kunming Medical University | Tianjin First Central Hospital | Tianjin Medical University Second Hospital | Henan Cancer Hospital | The Second H","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Novartis Pharmaceuticals Corporation | Qilu Hospital of Shandong University | The Second Affiliated Hospital of Kunming Medical University | Tianjin First Central Hospital | Tianjin Medical University Second Hospital | Henan Cancer Hospital | The Second H","highestDevelopmentStatusID":"8","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Novartis Pharmaceuticals Corporation | Qilu Hospital of Shandong University | The Second Affiliated Hospital of Kunming Medical University | Tianjin First Central Hospital | Tianjin Medical University Second Hospital | Henan Cancer Hospital | The Second H"},{"orgOrder":0,"company":"Fondazione IRCCS Policlinico San Matteo","sponsor":"University of Pavia | GSK | Azienda Ospedaliera di Padova | Azienda Ospedaliera di Perugia | Fondazione Telethon","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Fondazione IRCCS Policlinico San Matteo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione IRCCS Policlinico San Matteo \/ University of Pavia | GSK | Azienda Ospedaliera di Padova | Azienda Ospedaliera di Perugia | Fondazione Telethon","highestDevelopmentStatusID":"8","companyTruncated":"Fondazione IRCCS Policlinico San Matteo \/ University of Pavia | GSK | Azienda Ospedaliera di Padova | Azienda Ospedaliera di Perugia | Fondazione Telethon"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Cincinnati \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"University of Cincinnati \/ GSK"},{"orgOrder":0,"company":"University of Utah","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Utah \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"RenJi Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"RenJi Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RenJi Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"RenJi Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Amgen Inc"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway inhibitor","graph1":"Hematology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway inhibitor","graph1":"Hematology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Andexanet Alfa","moa":"Tissue factor pathway inhibitor | Apixaban | Rivaroxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Andexanet Alfa","moa":"Tissue factor pathway inhibitor | Apixaban | Rivaroxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"TNFRSF17","graph1":"Hematology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"The First Affiliated Hospital of Zhengzhou University","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Herombopag","moa":"TPO receptor","graph1":"Hematology","graph2":"Phase II","graph3":"The First Affiliated Hospital of Zhengzhou University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital of Zhengzhou University \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"The First Affiliated Hospital of Zhengzhou University \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Herombopag","moa":"TPO receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Hematology","graph2":"Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Weill Medical College of Cornell University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Hematology","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Danisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Vitamin K2","moa":"Trypanosoma Cruzipain (Trypano CYSP)","graph1":"Hematology","graph2":"Phase II","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Danisco \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Hematology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Hematology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Massachusetts General Hospital \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Incyte Corporation"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Red de Terapia Celular","sponsor":"University of Navarra Hospital (Cl\u00ednica Universitaria) | Haematology Service,University Hospital of Salamanca, M\u00aaConsuelo del Ca\u00f1izo Fern\u00e1ndez-Rold\u00e1n | Hospitales Universitarios Virgen del Roc\u00edo | Spanish National Health System","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Red de Terapia Celular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Red de Terapia Celular \/ University of Navarra Hospital (Cl\u00ednica Universitaria) | Haematology Service,University Hospital of Salamanca, M\u00aaConsuelo del Ca\u00f1izo Fern\u00e1ndez-Rold\u00e1n | Hospitales Universitarios Virgen del Roc\u00edo | Spanish National Health System","highestDevelopmentStatusID":"8","companyTruncated":"Red de Terapia Celular \/ University of Navarra Hospital (Cl\u00ednica Universitaria) | Haematology Service,University Hospital of Salamanca, M\u00aaConsuelo del Ca\u00f1izo Fern\u00e1ndez-Rold\u00e1n | Hospitales Universitarios Virgen del Roc\u00edo | Spanish National Health System"},{"orgOrder":0,"company":"Kind Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AND017","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Kind Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kind Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kind Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kind Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AND017","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Kind Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kind Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kind Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kind Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AND017","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Kind Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kind Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kind Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Graz","sponsor":"Novo Nordisk | CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRIA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Autologous Platelet","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Medical University of Graz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Graz \/ Novo Nordisk | CSL Behring","highestDevelopmentStatusID":"8","companyTruncated":"Medical University of Graz \/ Novo Nordisk | CSL Behring"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BAY 3018250","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BAY3018250","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Caphosol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Nantes University Hospital \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Nantes University Hospital \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"CSL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"CSL112","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Defearisox","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Albion","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Ferrous Bisglycinate","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Albion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albion \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Albion \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"FerruMax Pharmaceuticals","sponsor":"Davita Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"FMX-8","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"FerruMax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FerruMax Pharmaceuticals \/ Davita Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"FerruMax Pharmaceuticals \/ Davita Clinical Research"},{"orgOrder":0,"company":"Vascular Solutions LLC","sponsor":"U.S. Army Medical Materiel Development Activity | Westat","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Fresh Frozen Plasma","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Vascular Solutions LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascular Solutions LLC \/ U.S. Army Medical Materiel Development Activity | Westat","highestDevelopmentStatusID":"8","companyTruncated":"Vascular Solutions LLC \/ U.S. Army Medical Materiel Development Activity | Westat"},{"orgOrder":0,"company":"Genexine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"GX-E2","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genexine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/ Undisclosed"},{"orgOrder":0,"company":"Lagos State University","sponsor":"Health Forever Product Limited. Lagos, Nigeria","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NIGERIA","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Jobelyn","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Lagos State University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lagos State University \/ Health Forever Product Limited. Lagos, Nigeria","highestDevelopmentStatusID":"8","companyTruncated":"Lagos State University \/ Health Forever Product Limited. Lagos, Nigeria"},{"orgOrder":0,"company":"VitalMel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Lifemel","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"VitalMel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VitalMel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VitalMel \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MDCO-2010","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"Polysan","sponsor":"Atlant Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"RUSSIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Meglumine Sodium Succinate","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Polysan \/ Atlant Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Polysan \/ Atlant Clinical"},{"orgOrder":0,"company":"MegaPro Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MPB-1514","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"MegaPro Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MegaPro Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MegaPro Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Platelets","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"S&D Pharma SK s.r.o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SLOVAKIA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Probio-Fix Inum","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"S&D Pharma SK s.r.o.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S&D Pharma SK s.r.o. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"S&D Pharma SK s.r.o. \/ Undisclosed"},{"orgOrder":0,"company":"Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"RD01","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Angde Biotech Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Angde Biotech Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angde Biotech Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angde Biotech Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Entegrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Resusix","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Entegrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Entegrion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Entegrion \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR2285","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SSP-004184","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SSS06","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SSS17","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SSS17","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Trappa Ethanolamine","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"IG1202","moa":"Unknown","graph1":"Hematology","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Hematology","graph2":"Phase II","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cadrenal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Cadrenal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Hematology","graph2":"Phase II","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cadrenal Therapeutics \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Cadrenal Therapeutics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Tirol Kiniken GmbH","sponsor":"LFB Biomedicaments","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Von Willebrand Factor","moa":"von Willebrand factor","graph1":"Hematology","graph2":"Phase II","graph3":"Tirol Kiniken GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tirol Kiniken GmbH \/ LFB Biomedicaments","highestDevelopmentStatusID":"8","companyTruncated":"Tirol Kiniken GmbH \/ LFB Biomedicaments"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Simcah Management","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Cellphire Therapeutics \/ Simcah Management","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire Therapeutics \/ Simcah Management"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"HONG KONG","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Anfibatide","moa":"Platelet glycoprotein Ib alpha chain","graph1":"Hematology","graph2":"Phase II","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"John A. Widness","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ John A. Widness","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ John A. Widness"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Terrence J Bradley, MD","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Terrence J Bradley, MD","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Terrence J Bradley, MD"},{"orgOrder":0,"company":"Grifols International","sponsor":"Enrique Ginzburg","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Hematology","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Enrique Ginzburg","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Enrique Ginzburg"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Ayman Saad","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Orphan Biovitrum AB \/ Ayman Saad","highestDevelopmentStatusID":"8","companyTruncated":"Swedish Orphan Biovitrum AB \/ Ayman Saad"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Jason Robert Gotlib","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2013","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Hematology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Jason Robert Gotlib","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Jason Robert Gotlib"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Shayna Sarosiek, MD","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Hematology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Shayna Sarosiek, MD","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Shayna Sarosiek, MD"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"UMC Utrecht","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Hematology","graph2":"Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeOne Medicines \/ UMC Utrecht","highestDevelopmentStatusID":"8","companyTruncated":"BeOne Medicines \/ UMC Utrecht"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"William Shomali","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Hematology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ William Shomali","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ William Shomali"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rilzabrutinib Granted Orphan Drug Status in US for Two Rare Diseases

                            Details : SAR444671 (rilzabrutinib) is an investigational, oral, reversible, BTK inhibitor that has the potential to be a first- and best-in-class treatment of several immune-mediated diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 03, 2025

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIH...

                            Details : Rilzabrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Hemolytic, Autoimmune.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 12, 2021

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Isatuximab

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Ane...

                            Details : Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Hemolytic, Autoimmune.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 09, 2020

                            Lead Product(s) : Isatuximab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Semuloparin Sodium

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line

                            Details : Semuloparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thrombosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 30, 2012

                            Lead Product(s) : Semuloparin Sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Caplacizumab

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thr...

                            Details : Caplacizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Purpura, Thrombocytopenic.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 28, 2010

                            Lead Product(s) : Caplacizumab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University Health Network, Toronto

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            University Health Network, Toronto

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mitapivat

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Agios Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mitapivat Safety and Proof of Concept In RBC Membranopathies/CDAII

                            Details : Mitapivat is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Anemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 08, 2025

                            Lead Product(s) : Mitapivat

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Agios Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Shenyang Sunshine Pharmaceutical Co Ltd

                            China arrow
                            Florida Innovation
                            Not Confirmed

                            Shenyang Sunshine Pharmaceutical Co Ltd

                            China arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SSS17

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Dose-Finding of Oral SSS17 for Anemia in Non-Dialysis CKD

                            Details : SSS17 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Anemia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 11, 2025

                            Lead Product(s) : SSS17

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Shenyang Sunshine Pharmaceutical Co Ltd

                            China arrow
                            Florida Innovation
                            Not Confirmed

                            Shenyang Sunshine Pharmaceutical Co Ltd

                            China arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SSS17

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

                            Details : SSS17 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Anemia, Postoperative.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 06, 2025

                            Lead Product(s) : SSS17

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Shenyang Sunshine Pharmaceutical Co Ltd

                            China arrow
                            Florida Innovation
                            Not Confirmed

                            Shenyang Sunshine Pharmaceutical Co Ltd

                            China arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SSS06

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

                            Details : SSS06 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Anemia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : SSS06

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            TAHO Pharmaceuticals

                            Taiwan arrow
                            Florida Innovation
                            Not Confirmed

                            TAHO Pharmaceuticals

                            Taiwan arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apixaban

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TAHO Reports Positive Pivotal Study Results for Oral Dissolving Film TAH3311

                            Details : TAH3311 (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is being investigated for the treatment of thromboembolic conditions.

                            Product Name : Undisclosed

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            February 17, 2025

                            Lead Product(s) : Apixaban

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth